PharmAla Biotech To Supply LaNeo MDMA For Mt. Sinai Clinical Trial

PharmAla Biotech Holdings Inc. (OTC:MDXXF) has announced that it will supply its Good Manufacturing Practice LaNeo MDMA for a clinical trial at Mt. Sinai Health System. The biotechnology company specializes in the research, development, and production of MDMA and novel MDXX-class molecules.

"We're looking forward to supporting the team at Mt. Sinai Health System with high-quality clinical trial drug product,” said Nicholas Kadysh. “Sinai houses some of the best researchers in the world… and has fantastic new facilities for MDMA-assisted therapy."

The trial at Mt. Sinai will focus on MDMA-assisted therapy, with the potential for further collaboration. Researchers can access detailed product quality information for clinical trials through PharmAla's online portal.

This announcement follows Pharmala’s selection as a supplier for a clinical trial at the University of Texas, San Antonio, earlier this month.

Termination Of CCrest Labs Agreement

In other news, PharmAla has terminated its 2022 agreement with CCrest Labs, which was distributing MDMA under the Special Access Program. PharmAla will now rely on other distributors to continue its work.

Cover image made with AI